HC Wainwright Analysts Boost Earnings Estimates for VNDA

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities research analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a research report issued to clients and investors on Monday, January 5th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings per share of ($0.24) for the quarter, up from their previous estimate of ($0.26). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.36) EPS.

VNDA has been the topic of a number of other reports. B. Riley boosted their price objective on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, December 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, October 8th. UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, December 17th. Finally, Wall Street Zen upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Vanda Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $13.63.

Vanda Pharmaceuticals Trading Down 14.1%

Shares of Vanda Pharmaceuticals stock opened at $7.34 on Wednesday. The firm’s 50 day simple moving average is $5.93 and its two-hundred day simple moving average is $5.19. The firm has a market capitalization of $433.79 million, a price-to-earnings ratio of -5.17 and a beta of 0.60. Vanda Pharmaceuticals has a 12-month low of $3.81 and a 12-month high of $9.60. The company has a current ratio of 3.12, a quick ratio of 3.10 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.07). The company had revenue of $56.26 million during the quarter, compared to analysts’ expectations of $58.73 million. Vanda Pharmaceuticals had a negative net margin of 39.70% and a negative return on equity of 16.82%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of VNDA. Stonepine Capital Management LLC boosted its position in Vanda Pharmaceuticals by 611.3% in the 2nd quarter. Stonepine Capital Management LLC now owns 250,000 shares of the biopharmaceutical company’s stock worth $1,180,000 after purchasing an additional 214,852 shares in the last quarter. Squarepoint Ops LLC increased its holdings in shares of Vanda Pharmaceuticals by 96.5% during the 2nd quarter. Squarepoint Ops LLC now owns 153,345 shares of the biopharmaceutical company’s stock valued at $724,000 after purchasing an additional 75,295 shares in the last quarter. R Squared Ltd acquired a new position in shares of Vanda Pharmaceuticals in the 2nd quarter valued at $83,000. MetLife Investment Management LLC boosted its holdings in Vanda Pharmaceuticals by 18.9% during the first quarter. MetLife Investment Management LLC now owns 32,816 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 5,210 shares in the last quarter. Finally, PVG Asset Management Corp purchased a new stake in Vanda Pharmaceuticals during the first quarter worth $48,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised near-term EPS estimates for VNDA (Q1–Q3 and FY2026) and maintains a Buy rating with a $22 price target — this reflects analyst confidence in the company’s longer-term prospects despite the setback.
• Neutral Sentiment: BusinessWire reports a merger between a company named Vanda and Exante Data; the press release appears to describe a data/analytics firm and may not be related to Vanda Pharmaceuticals (VNDA). Investors should verify whether this announcement applies to VNDA via company filings. Vanda and Exante Data Combine in Strategic Merger
• Negative Sentiment: FDA decision letter: CDER concluded the HETLIOZ jet-lag sNDA cannot be approved in its current form after the collaborative re-review. That directly removes a near-term regulatory catalyst and potential revenue expansion for HETLIOZ. Official company release: Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ sNDA
• Negative Sentiment: Market coverage and headlines (MSN, Investing.com, etc.) reported the FDA rejection and consequent premarket/early-session selling, which drove the intraday decline and higher-than-average volume. Example coverage: Vanda shares slide after FDA turns down jet lag use for HETLIOZ

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.